We're Hopeful That Skye Bioscience (NASDAQ:SKYE) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech ...
Solid Biosciences (NASDAQ:SLDB) Price Target Raised to $16.00
Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...
What is Wedbush’s Estimate for RCUS FY2029 Earnings?
Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Arcus Biosciences in a note issued to investors ...
STAT3d
FDA cuts, zombie biotechs, and too much weight loss?
On The Readout LOUD this week, STAT reporters discuss the FDA's staff cuts, how next-gen drugs may lead to too much weight ...
Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 50.8% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, ...
Hosted on MSN4d
Solid Biosciences’ stock soars on early success in DMD gene therapy trial
The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.
IFF projects 1-4% revenue growth in 2025 with focus on R&D and capacity expansion
Discover IFF's Q4 2024 earnings highlights, strategic investments in innovation, rising sales, and operational efficiency.